References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492.
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:https://doi.org/10.1038/nature25183.
- Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65(1):30–54. doi:https://doi.org/10.3322/caac.21261.
- Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709–719. doi:https://doi.org/10.1016/S0140-6736(13)61502-0.
- Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5(1):29–33. doi:https://doi.org/10.1097/JTO.0b013e3181c5920c.
- Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12(9):511–526. doi:https://doi.org/10.1038/nrclinonc.2015.90.
- Liu J, Du W, Fan D. Survivin, the promising target in hepatocellular carcinoma gene therapy. Cancer Biol Ther. 2008;7(4):555–556. doi:https://doi.org/10.4161/cbt.7.4.5891.
- Koh YW, Han JH, Haam S, Jung J. ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data. J Cancer Res Clin Oncol. 2019;145(6):1427–1436. doi:https://doi.org/10.1007/s00432-019-02906-2.
- Li B, Meng YQ, Li Z, et al. MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):3286–3296. doi:https://doi.org/10.1080/21691401.2019.1648283.
- Kim TY, Jackson S, Xiong Y, et al. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci USA. 2013;110(42):16868–16873. doi:https://doi.org/10.1073/pnas.1306358110.
- Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998;58(10):2196–2199.
- Joshi R, Qin L, Cao X, et al. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA. J Biol Chem. 2020;295(2):645–656. doi:https://doi.org/10.1074/jbc.RA119.011929.
- Yang X, Popescu NC, Zimonjic DB. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res. 2011;71(8):2916–2925. doi:https://doi.org/10.1158/0008-5472.CAN-10-2158.
- Akagi I, Okayama H, Schetter AJ, et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 2013;73(13):3821–3832. doi:https://doi.org/10.1158/0008-5472.CAN-13-0031.
- Li Y, Ye Z, Chen S, et al. ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer. Int J Cancer. 2018;142(7):1379–1391. doi:https://doi.org/10.1002/ijc.31169.
- Gomez-Sarosi LA, Strasberg-Rieber M, Rieber M. ERK activation increases nitroprusside induced apoptosis in human melanoma cells irrespective of p53 status: role of superoxide dismutases. Cancer Biol Ther. 2009;8(12):1173–1182. doi:https://doi.org/10.4161/cbt.8.12.8561.
- Stadheim TA, Kucera GL. c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res. 2002;26(1):55–65. doi:https://doi.org/10.1016/S0145-2126(01)00099-6.
- Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 2008;22(11):1439–1444. doi:https://doi.org/10.1101/gad.1672608.
- Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 2004;14(7):377–385. doi:https://doi.org/10.1016/j.tcb.2004.05.003.
- Lahoz A, Hall A. DLC1: a significant GAP in the cancer genome. Genes Dev. 2008;22(13):1724–1730. doi:https://doi.org/10.1101/gad.1691408.
- Gokmen-Polar Y, True JD, Vieth E, et al. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. PLoS One. 2018;13(10):e0204658. doi:https://doi.org/10.1371/journal.pone.0204658.
- Wu HT, Xie CR, Lv J, et al. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma. Lab Invest. 2018;98(8):1014–1024. doi:https://doi.org/10.1038/s41374-018-0062-3.
- Su Y, Lin L, Zhang J, et al. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Mol Med Rep. 2015;12(4):5771–5779. doi:https://doi.org/10.3892/mmr.2015.4173.
- Du X, Qian X, Papageorge A, et al. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res. 2012;72(17):4405–4416. doi:https://doi.org/10.1158/0008-5472.CAN-12-0777.
- Durkin ME, Yuan BZ, Zhou X, et al. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 2007;11(5):1185–1207. doi:https://doi.org/10.1111/j.1582-4934.2007.00098.x.
- Wu Z, Li Y, Zhang G. Downregulation of microRNA-301a inhibited proliferation, migration and invasion of non-small cell lung cancer by directly targeting DLC1. Oncol Lett. 2017;14(5):6017–6023. doi:https://doi.org/10.3892/ol.2017.6990.
- Swanton C, Govindan R. Clinical Implications of Genomic Discoveries in Lung Cancer. N Engl J Med. 2016;374(19):1864–1873. doi:https://doi.org/10.1056/NEJMra1504688.
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.